IRONWOOD PHARMACEUTICALS INC

Pharmaceutical Preparations

IRWD Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001446847 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$674.18M
165,239,947 shares Covers every share class this company has on file.
Insiders on file
11
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$105.22M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
15.61%
insider-held value divided by market capitalisation

What IRONWOOD PHARMACEUTICALS INC reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$296.15M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
$24.02M
FY2025 profit for the period, from this company’s own annual XBRL filings to the SEC
Employees
100
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at IRONWOOD PHARMACEUTICALS INC

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against IRONWOOD PHARMACEUTICALS INC.
Insider Reported role Shares Value Last action
Officers 6
Michael Shetzline SVP 1,179,462 $5.02M A Grant or award Mar 10, 2026 position reported
Minardo John General Counsel 500,498 $2.13M A Grant or award Mar 10, 2026 position reported
Ronald Silver Chief Accounting Officer 416,570 $1.77M S Open-market sale Jul 7, 2026 position reported
Tammi L Gaskins Other Executive 350,350 $1.49M A Grant or award Mar 10, 2026 position reported
Gregory S Martini CFO 297,213 $1.27M A Grant or award Mar 10, 2026 position reported
Andrew Davis SVP 284,685 $1.21M S Open-market sale Nov 18, 2024 position reported
Officers who also sit on the board 2
Thomas A McCourt Thomas A McCourt CEO 1,898,838 $8.09M A Grant or award Mar 10, 2026 position reported
Sravan Kumar Emany CFO 309,572 $1.32M S Open-market sale Nov 18, 2024 position reported
Directors 3
Alexander J. Denner Board Member 18,639,379 $79.40M A Grant or award Jun 16, 2026 position reported
Mark G Currie Board Member 613,419 $2.61M A Grant or award Jun 16, 2026 position reported
Julie McHugh Julie McHugh Board Member 208,839 $889.7K S Open-market sale Jun 16, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Ronald Silver sold 127,890 IRONWOOD PHARMACEUTICALS INC (IRWD) shares for $578,063 on Jul 7, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Ronald Silver sold 127,890 IRONWOOD PHARMACEUTICALS INC (IRWD) shares for $578,063 on Jul 7, 2026
Date Insider Transaction Shares Price Value Filing
Jul 7, 2026 Ronald Silver S Open-market sale 127,890 held after: 313,680 $4.52 $578,063 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Ronald Silver sold 127,890 IRONWOOD PHARMACEUTICALS INC (IRWD) shares for $578,063 on Jul 7, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Ronald Silver sold 127,890 IRONWOOD PHARMACEUTICALS INC (IRWD) shares for $578,063 on Jul 7, 2026
Date Insider Transaction Shares Price Value Filing
Jul 7, 2026 Ronald Silver S Open-market sale 127,890 held after: 313,680 $4.52 $578,063 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 72 rows we hold, 0 are open-market purchases and 38 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for IRONWOOD PHARMACEUTICALS INC, newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Jul 7, 2026 Ronald Silver S Open-market sale 127,890 $4.52 $578.1K SEC filing ↗
Jun 16, 2026 Mark G Currie A Grant or award 63,481 $0.00 $0 SEC filing ↗
Jun 16, 2026 Alexander J. Denner A Grant or award 63,481 $0.00 $0 SEC filing ↗
Jun 16, 2026 Julie McHugh S Open-market sale 21,571 $3.73 $80.5K SEC filing ↗
Jun 16, 2026 Julie McHugh A Grant or award 63,481 $0.00 $0 SEC filing ↗
Jun 15, 2026 Alexander J. Denner A Grant or award 4,065 $0.00 $0 SEC filing ↗
May 19, 2026 Ronald Silver A Grant or award 25,000 $0.00 $0 SEC filing ↗
Mar 17, 2026 Alexander J. Denner S Open-market sale 6,725,000 $3.05 $20.51M SEC filing ↗
Mar 17, 2026 Alexander J. Denner S Open-market sale 5,800 $3.31 $19.2K SEC filing ↗
Mar 13, 2026 Alexander J. Denner A Grant or award 4,451 $0.00 $0 SEC filing ↗
Mar 10, 2026 Michael Shetzline A Grant or award 136,612 $0.00 $0 SEC filing ↗
Mar 10, 2026 Tammi L Gaskins A Grant or award 136,612 $0.00 $0 SEC filing ↗
Mar 10, 2026 Gregory S Martini A Grant or award 136,612 $0.00 $0 SEC filing ↗
Mar 10, 2026 Minardo John A Grant or award 136,612 $0.00 $0 SEC filing ↗
Mar 10, 2026 Ronald Silver A Grant or award 163,934 $0.00 $0 SEC filing ↗
Mar 10, 2026 Thomas A McCourt A Grant or award 409,836 $0.00 $0 SEC filing ↗
Feb 24, 2026 Michael Shetzline S Open-market sale 17,012 $3.66 $62.3K SEC filing ↗
Feb 24, 2026 Tammi L Gaskins S Open-market sale 11,239 $3.66 $41.1K SEC filing ↗
Feb 24, 2026 Gregory S Martini S Open-market sale 11,457 $3.66 $41.9K SEC filing ↗
Feb 24, 2026 Minardo John S Open-market sale 19,053 $3.66 $69.7K SEC filing ↗
Feb 24, 2026 Ronald Silver S Open-market sale 12,621 $3.66 $46.2K SEC filing ↗
Feb 24, 2026 Thomas A McCourt S Open-market sale 103,526 $3.66 $378.9K SEC filing ↗
Feb 23, 2026 Michael Shetzline S Open-market sale 15,570 $3.81 $59.3K SEC filing ↗
Feb 23, 2026 Tammi L Gaskins S Open-market sale 10,287 $3.81 $39.2K SEC filing ↗
Feb 23, 2026 Gregory S Martini S Open-market sale 10,487 $3.81 $40.0K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 1 filer holds a position

Who owns IRONWOOD PHARMACEUTICALS INC

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 1 of the positions below was reported on a filing shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in IRONWOOD PHARMACEUTICALS INC

Funds, trusts and companies that disclose an ownership position in IRONWOOD PHARMACEUTICALS INC.
Owner Reported role Shares Filed
Sarissa Capital Management LP TenPercentOwner 16,171,293 joint

See the full ownership map — every entity that files as an owner of a US public company.

Subsidiaries — 4 legal entities

Subsidiaries of IRONWOOD PHARMACEUTICALS INC

4 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries IRONWOOD PHARMACEUTICALS INC names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
GlyPharma Therapeutic Inc Canada
Ironwood Pharmaceuticals GmbH Switzerland
Ironwood Pharmaceuticals Securities Corporation Massachusetts
VectivBio AG Switzerland
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from IRONWOOD PHARMACEUTICALS INC’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from IRONWOOD PHARMACEUTICALS INC’s own SEC filings multiplied by the closing price we hold for the same stock.